ArticlePharmaceuticals (Basel, Switzerland)2024

Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System.

Giuseppe Cicala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.